| Filed On | Filing |
|---|---|
| 26 Oct 2026 |
8-K: Regulation FD Disclosure; Other Events
On October 26, 2026, Cumberland Pharmaceuticals Inc. (the “Company” or “Cumberland”), an innovation-focused biopharmaceutical company developing new products for rare diseases, issued a press release providing an update on its ifetroban ... |
| 23 Oct 2026 |
8-K: Other Events
On October 23, 2026, Cumberland Pharmaceuticals Inc. (“Cumberland”) announced top-line results from its Phase 2a ASSIST-SSc trial evaluating oral ifetroban for patients with systemic sclerosis. These results support the safety and tolera... |
| 11 Sep 2026 |
8-K/A: Submission of Matters to a Vote of Security Holders
At the 2026 Annual Meeting, the Company’s shareholders voted on, among other matters, an advisory proposal concerning the frequency of future advisory votes on compensation of the Company's named executive officers. As originally reporte... |
| 28 Aug 2026 | 8-K: Regulation FD Disclosure |
| 07 Aug 2026 | 10-Q |
| 04 Aug 2026 | 8-K: Results of Operations and Financial Condition |
| 13 Jul 2026 | 8-K: Other Events |
| 01 Jul 2026 | 8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +3 more |
| 25 Jun 2026 | 8-K: Submission of Matters to a Vote of Security Holders |
| 26 May 2026 | Merger proxy: special meeting on June 24, 2026 |
| 15 May 2026 | PREM14A |
| 08 May 2026 | 10-Q |
| 05 May 2026 | 8-K: Results of Operations and Financial Condition |
| 24 Apr 2026 | 8-K: Submission of Matters to a Vote of Security Holders |
| 23 Apr 2026 | DEFA14A |
| 23 Apr 2026 | 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure +1 more |
| 20 Mar 2026 |
Form 4: Anthony Todd M., Vice Pres Organizational Dev
Granted 3,000 Options (right to buy) ($8.4K) |
| 20 Mar 2026 |
Form 4: Bitterman Chris T., Vice Pres Sales & Marketing
Granted 3,000 Options (right to buy) ($8.4K) |
| 20 Mar 2026 |
Form 4: Hamm John M., VP Chief Financial Officer
Granted 3,000 Options (right to buy) ($8.4K) |
| 20 Mar 2026 |
Form 4: Herman James L, VP and Chief Compliance Office
Granted 2,500 Options (right to buy) ($7K) |
Loading...
